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www.cdatm.orgKeywords: Breast neoplasms; Prevention; ChinaBreast cancer is the most common malignancy and
the fourth leading cause of cancer-related death among
Chinese females. And in the past two decades, there
has been an ever-increasing incidence of breast cancer
in both urban and rural areas in China, resulting in a
great social and economic burden. Prevention has been
proved to be one of the most important ways to control
disease burden. However, because of the national
condition, currently the prevention of breast cancer in
China is far away from being satisfactory or effective.
Here, we reviewed the epidemiology characteristics,
the risk factors, and the current screening efforts of
breast cancer in China. Also, we discuss alternative
ways to improve the prevention work of breast cancer
in China.
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open access article under the CC BY-NC-ND license (http://creativecommwith an estimated 1.67 million new cancer cases
diagnosed in 2012 (25% of all cancers).1 Traditionally,
China was believed to be among low-incidence areas
of breast cancer.2 However, in the past two decades,
China experienced an ever-increasing incidence of
breast cancer, twice as fast as global rates.2 According
to the latest Chinese Cancer Registry Annual Report,3
breast cancer has become the most common cancer
among Chinese women and ranked the fifth leading
cause of cancer-related deaths. In consideration of the
huge population base of 1.34 billion,4 China is facing
increasing enormous social and economic burden of
breast cancer. Prevention has been proved to be one of
the most effective methods to hold the increasing
chronic disease burden. However, because of the so-
cioeconomic disparities and insufficient financial re-
sources, by far, prevention of breast cancer has not
been well carried out in China.5,6 Health ministry and
health-care systems are facing many challenges caring
for patients with breast cancer and population at
increased risk of breast cancer: inadequate funding;
inequitable distribution of resources and services;
inadequate numbers, training, and distribution of
health-care personnel and equipment; lack of adequate
care for many populations based on socioeconomic,
geographic and other factors.Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an
ons.org/licenses/by-nc-nd/4.0/).
3F. Wang, Z.-G. Yu / Chronic Diseases and Translational Medicine 1 (2015) 2e8Here, we review the epidemiology characteristics,
the risk factors, and the current screening efforts of
breast cancer in China. Also, we discuss alternative
ways to improve the prevention work of breast cancer
in China.
Disease burden of breast cancer
According to Globocan 2012 by WHO,1 an esti-
mated 187,000 new breast cancer cases were diagnosed
in China in 2012, accounting for nearly 12% of the
whole world new breast cancer cases, with an age-
standardized rate (ASR) of 22.1 cases per 100,000
women, while 48,000 females died from breast cancer,
accounting for about 9% of the whole world, with an
ASR of 5.4 cases per 100,000 women. The Chinese
Cancer Registry Annual Report 20133 showed that
breast cancer is the most common malignancy among
Chinese females, with an estimated incidence of 25.89
cases per 100,000 women. On the other hand, breast
cancer is the fourth leading cause of cancer-related
death among Chinese females, after lung cancer,
gastric cancer, and liver cancer, with an estimated
mortality of 6.56 cases per 100,000 women. Similar to
other regions, there was an obvious urbanerural dif-
ference in incidence of breast cancer. The incidence in
urban areas (47.79 cases per 100,000 women) is nearly
twice as high as that in rural areas (27.72 cases per
100,000 women). And this urbanerural difference
pattern was also observed in local cancer registry report,
such as Jiangsu Province.7 In the past 15 years between
1993 and 2008, there has been a sharp increase in breast
cancer incidence in both urban and rural areas, with an
estimated annual increase rate of 3.7% and 8.9%,
respectively.8,9 As a result, the gap in breast cancer
incidence between rural and urban areas has been nar-
rowing, especially in some developed areas such as
Beijing.10 And a cross-sectional study covering Shan-
dong Province, Jiangsu Province, Hebei Province, and
Tianjin also demonstrated a similar prevalence of breast
cancer between urban and rural areas.11 This narrowing
trend may be related to the national urbanization. And at
the above increase rate, it was expected that there would
be more than 2.5 million breast cancer cases by 2021.12
Themean age at diagnosis of breast cancer in China is
45e55 years, much more younger than 65 years in the
United States and as well as other western countries.13
Traditionally, there is an interesting double-peak
pattern in age-specific incidence curve of breast cancer
in themainland of China, one peak at about 45e55 years
and another at 70e74 years.2,14 Similarly in Taiwan of
China and Hong Kong of China, such double-peakpattern was reported.15e17 The unique peak in age-
specific incidence at 45e55 years might be due to
shifts in risk factor profiles such as menstrual and
reproductive characteristics.18 However, data from
Beijing 10 showed that during 2004 and 2008, the peak
age group of the female breast cancer incidence in urban
areas was 60e64 years, whereas in rural areas the peak
was, respectively, at 50e54 and 80e84 years. This result
indicated a shift trend to western patterns with an older
median age at diagnosis, especially in developed areas. It
was estimated that by 2030, 27.0%of breast cancer cases
would be diagnosed at age older than 65 years, while in
2008 this number is only 16.6%.19
Data from 16 population-based cancer registries
during 2003e200520 showed that the 5-year survival
rate of female breast cancer cases in China was 73.0%,
ranking the first in all cancers. And survival for rural
patients was about half that of their urban counterparts.
Compared to 89.0% of the United States,21 there is still
quite a lot to be improved.
However, it is not possible to describe the accurate
incidence and mortality of breast cancer in China,
because the cancer registry system is not well estab-
lished.22,23 By 2013, there were only 249 cancer reg-
istries in China, covering 31 provinces with about 200
million people, accounting for about 15.42% of Chi-
nese population.22 While in the United States, about
96% patients were included in health-care system such
as National Program of Cancer Registries (NPCR) by
Centers for Disease Control23 and Surveillance,
Epidemiology, and End Results (SEER) Program by
National Cancer Institute.24 This deficiency of data has
become a big bottleneck for the development of cancer
control policy. Since 2012, cancer registry programs
based on hospitals have been carried out in several
provinces in China, but still not well developed. And
there are some shortcomings in the above programs,
such as insufficient extensions and integrity, distribu-
tion disproportion, lacking of necessary quality control
and like.25 With the expansion of China's cancer reg-
istry, anyhow, the accuracy of breast cancer burden
estimates would be improved and more representative.
Risk factors of breast cancer in China
A number of caseecontrol studies have been con-
ducted to explore the risk factors of breast cancer in
different areas, but resulted in a relatively consistent
conclusion.26 Traditional risk factors such as a long
menstrual life, nulliparity, later age at first birth, and
limited breastfeeding are associated with increased risk
of breast cancer in the Chinese population,11,27,28
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the numbers of birth, different results were reported.
Bao et al29 found that increased numbers of births per
woman were associated with a reduced risk of breast
cancer (OR ¼ 0.69, 95% CI: 0.52e0.91) for post-
menopausal women. While in Yu's study,11 no associ-
ation between numbers of birth and risk of breast
cancer was observed. This may be related to the one-
child policy. Most population, especially younger
women, have no more than one child, and affected by
traditional family views, especially in rural areas,
childless families are rare.
Diabetes mellitus was reported to be associated with
a 10e20% excessive risk of breast cancer,30 and a
meta-analysis by Hardefeldt31 showed that type 2
diabetes mellitus could increase female breast cancer
risk by 22% (OR ¼ 1.22, 95% CI: 1.07e1.40). How-
ever, in China, little attention has been paid to diabetes
mellitus, and only one study by Wang et al32 showed a
similar association in Chinese population (OR ¼ 3.35,
95% CI 1.02e11.01). Similar to breast cancer, diabetes
mellitus is another public health focus. With the
increased life expectancy and changing lifestyles, the
incidence of diabetes mellitus in China has increased
four fold in the last two decades.33 By 2008, there were
92.4 million adults with diabetes (50.2 million men and
42.2 million women) and 148.2 million adults with
prediabetes (76.1 million men and 72.1 million
women).34 So it is vital to know whether there is any
association between the increase in diabetes mellitus
and breast cancer.
It has been proven in many epidemiological stud-
ies35e37 that obesity, especially postmenopausal obesity,
is associated with breast cancer, and earlier obesity onset
is related to higher breast cancer risk.38 The study by
Sun38 showed that in China women with a body mass
index (BMI) of 24 kg/m2 or higher had a four-fold
increased risk of breast cancer compared with those less
than 24 kg/m2. And similar association was also reported
by Yu33 (OR ¼ 1.696). At present, nearly 30% women
were reported as being overweight (BMI 25 kg/m2) or
obese (BMI 30 kg/m2) in China.39 Besides, obesity is
closely associated with type 2 diabetes mellitus, and
among type 2 diabetes mellitus patients in China the
prevalence of obesity could reach more than 30%. Thus,
the potential combined effects of diabetes mellitus and
obesity on the increase of breast cancer incidence should
be paid attention to.40
As to some other factors such as breast density,41,42
which have been well investigated in western studies,
due to lack of attention, no definite associationwith breast
cancer risk among Chinese women could be drawn.Current screening of breast cancer in China
In consideration of the high incidence, screening is
believed to be one of the most important methods to
prevent breast cancer, and it has been proved in both
Swedish and the United States trials that mammog-
raphy screening could reduce breast cancer mortality
risk by about 20%.43,44 In China, there has been no
such large-scale or long-term follow-up trial, but data
from some local screening programs have proved that
screening could help detect early stage breast cancer.
In Guangzhou screening program,45 the early breast
cancer detective rate was 84.1%, about 5% higher than
that among in-hospital patients (79.3%). While as to
0eI stage diseases, the detective rate was 47.0% and
37.2% among screening and in-hospital populations,
respectively. Similar early detective rates were also
reported in three Shanghai programs.
However, by now, there has been no nationwide
screening program of breast cancer. Once in 2005,
China government started a national population-based
screening program of breast cancer.46 This program
was aimed to screen 100,000 women with both
mammography and breast ultrasonography, but
stopped 2 years later due to the insufficient financial
funding support and the concern about false-positive.
In fact, there are several barriers for large-scale pop-
ulation-based screening for breast cancer in China.
First, China bears an enormous population of more
than 652 million females,4 and substantial external
financial resources are needed to cover such large-scale
screening. More importantly, there are insufficient
convincing cost-effectiveness data by far. Cost-
effectiveness analysis of local breast cancer screening
in Shanghai showed that it costs about RMB Yuan
120,000 through screening to detect one breast cancer
case, while RMB Yuan 211,000 for each early stage
cases. In Guangdong Province,45 at least 1339 females
should be screened to detect one new breast cancer
case. And in Shanghai, the cost for each early detective
breast cancer was at least RMB Yuan 90,000 or at most
RMB Yuan 284,000, depending on different age
groups, nearly equal to one or three times of the real
GDP per capita of Guangzhou in 2010 (RMB Yuan
88,000).45 Whereas among Hong Kong Chinese fe-
males,47 the incremental cost-effectiveness ratio
(ICER) of mammography screening was US $ 61,600
per QALY saved, and the probability of the ICER
being below a threshold of US$ 50,000 per QALY was
only 15.3%. Obviously, population-based breast cancer
screening is not financially worthwhile in all the above
three areas. Second, even though the health education
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public awareness of breast cancer is still quite low. A
cross-sectional epidemiology survey covering more
than 120,000 females48 showed that 81.4% of partici-
pants were poorly aware of breast cancer. As a result,
few females would like to spend money on
mammography or ultrasonography screening, and the
screening rates were quite low from 11.38% to 19.2%
in different areas,49 far below that of 301.0/1000 in the
United States.50 And third, because of the large, widely
dispersed population and the huge urbanerural gap,
there is quite a shortage of mammography and ultra-
sonography equipments, especially in rural areas.
As to the screening rationale, different screening
patterns have been employed in different screening
programs. Compared to the well-accepted benefit of
mammography screening in western countries,43,51 it
has been a long time since the controversy of
mammography screening, ultrasonography screening,
and clinical breast examination screening was raised in
China. Following national guidelines,52 annual
mammography for women aged 40e49 years and
every 1e2 years for those aged 50e69 years is rec-
ommended. However, in view of the earlier diagnosis
age and the higher breast density of Chinese women,
mammography was traditionally supposed to be not as
sensitive as that among European or American women.
A meta-analysis by Kang53 showed that among Asian
females, the sensitivity of mammography screening
was 0.845 (95% CI: 0.821e0.870), much lower than
that among western countries (0.95, 95% CI:
0.93e0.96). And findings from a study in Beijing54
showed that only 5.2% of new breast cancer cases
were detected by routine mammographic screening,
whereas 82.1% of cases experienced obvious symp-
toms at diagnosis, while the proportion of breast can-
cers detected through mammography screening is
about 60% in the United States.55 However, a
population-based randomized trial56 demonstrated that
among women aged 40e49, mammography showed a
higher sensitivity of invasive breast cancer detection
than ultrasonography (96% vs. 75%) and suggested
that alternating ultrasonography screening was an
effective complement to mammography screening
among young women. At present, there is no meth-
odologically sound evidence available justifying the
routine use of ultrasonography as an adjunct screening
tool in women at average risk for breast cancer.57 In
Beijing breast cancer screening program covering
568,000 women,58 ultrasonography was employed as
the only screening tool, and the detective rate was only
47.83/100,000, whereas the incidence of breast cancerin the same year was 58.22/100,000.59 But as reported
by Xu,45 during 6-year screening based on breast ul-
trasonography among 8753 women, the proportion of
early stage breast cancer detected was 58.33%, much
higher than that of the national mammography
screening (31.11%). In this study, the detective rate of
breast cancer was 77.78/100,000, and when com-
plemented by mammography, the rate could be raised
further to 88.89/100,000. In consideration of the lower
price of ultrasonography and the denser breast tissue of
Chinese women, this study indicated that screening
based on ultrasonography may be considered as a
preferred pattern of breast cancer screening in China.
As to the breast examination, early in the 1980s, the
randomized screening trial in Shanghai60 demonstrated
that after 12-year follow-up, breast self-examination
failed to neither improve early diagnosis rate nor
reduce mortality. Nonetheless, as it could somewhat
improve public awareness, self-examination was taken
as an important part of health education.61 At present,
there has been no consensus about the role of clinical
breast examination for early detection. But in current
domestic screening practice, clinical breast examina-
tion is always employed in combination with ultraso-
nography or/and mammography.
Risk-based screening: an alternative way
At present, not only in China, but also around the
world, it is not definite which screening pattern is
optimized. There are two important factors that we
have to take into consideration before the final
personalized screening patterns are established. One is
the balance between harm and benefit and another one
is the ratio of cost to effectiveness.
But on the whole, the one-size-fits-all paradigm in
organized screening of breast cancer is shifting toward
a personalized approach.62 It has been proved in a
Spanish study that compared to traditional uniform
screening pattern, risk-based strategies resulted in a
much higher benefit for a specific cost.62 Enhanced
strategies to identify the highest risk population should
be research priorities.63 And as recommended by
NCCN guidelines of breast cancer screening and
diagnosis,64 Gail-2 model is advised to be employed
for discriminating normal risk and increased risk
population, by which different screening follow-ups
are conducted. Though well validated and approved
in American women, Gail-2 model was not suitable for
Chinese women.65 Thus there is an urgent need to
explore and establish a risk assessment tool suitable for
Chinese women and China's actual conditions. Based
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Yu et al presented a new risk model including six
factors: diabetes mellitus, BMI, family history of
breast cancer, personal history of benign breast disease,
age at first birth, miscarriages times, and current life
satisfactory degree. The area under ROC curve (AUC)
for 5-year risk of this model is 0.717, better than Gail
model. And worth to mention, this model could work
without any assistant examination such as ultrasonog-
raphy and mammography. So it is particularly well
suited for application in community and villages. On
this basis, a two-step risk assessment system was
proposed. In this system, with the help of an elemen-
tary risk tool (for community use), women at suspi-
cious high risk could be selected. And after further
screening by another professional risk tool (for hospital
use), in which ultrasonography and mammography are
included, the women at true high risk are selected
finally for long-term follow-up. As described before, a
principal challenge to population-based screening of
breast cancer in China is the gap between the enor-
mous, widely dispersed population and limited finan-
cial funding. So this two-step system is a convenient
and economical way for breast cancer screening in
China. At present, the critical work is to further opti-
mize the elementary risk tool and to establish the
professional tool.
In a word, risk-based strategies are expected to
reduce harm and costs. And it is necessary to develop
accurate measures of individual risks and to work on
how to implement the strategies at the most.
Conclusion
Breast cancer has been a great social and econom-
ical burden for China, but there is still quite a long way
to improve the prevention. Breast cancer control efforts
should include not only health-care delivery, but also
public participation to increase awareness and pro-
motion of early detection.
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